Filtered By:
Drug: Temodar

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 1478 results found since Jan 2013.

Aurora kinase B siRNA-loaded lactoferrin nanoparticles potentiate the efficacy of temozolomide in treating glioblastoma
Nanomedicine, Ahead of Print.
Source: Future Medicine: Nanomedicine - October 18, 2018 Category: Nanotechnology Authors: Sonali Kumari Dwaipayan Bhattacharya Nandini Rangaraj Sumana Chakarvarty Anand K Kondapi Nalam M Rao Source Type: research

G3BP1 knockdown sensitizes U87 glioblastoma cell line to Bortezomib by inhibiting stress granules assembly and potentializing apoptosis
ConclusionOur data suggest G3BP1 knockdown diminishes SG formation and stimulates BZM-induced apoptosis of U87 cells in vitro, in addition to inhibiting glioblastoma-induced angiogenesis in vivo.
Source: Journal of Neuro-Oncology - August 6, 2019 Category: Cancer & Oncology Source Type: research

Snail expression contributes to temozolomide resistance in glioblastoma.
Authors: Liang H, Chen G, Li J, Yang F Abstract Glioblastoma (GBM) is one of most malignancy tumors worldwide. Temozolomide (TMZ) is an important chemotherapy drug in GBM therapy. However, acquired TMZ-resistance frequently happens in GBM therapy and leads to high percentage of GBM recurrence. In our study, we demonstrated that Snail is upregulated in recurrent GBM tumors, and promotes the GBM cells resistant to TMZ induced apoptosis. Enhanced expression of Snail compromises the apoptosis induced by TMZ, and increases the cell migration and invasion. Reversely, depletion of Snail by siRNA has the opposite effects. ...
Source: American Journal of Translational Research - August 11, 2019 Category: Research Tags: Am J Transl Res Source Type: research

43PXAF1 enhances temozolomide induced autophagic cell death through AMPK signaling pathway
ConclusionsEpigenetic inactivation of XAF1 contributes to the malignant progression of human glioma by rendering tumor cells a survival advantage via the attenuation of AMPK signaling.Legal entity responsible for the studyThe authors.FundingNational Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2018R1D1A1B07041512).DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - October 1, 2019 Category: Cancer & Oncology Source Type: research

Knockdown of Tousled ‑like kinase 1 inhibits survival of glioblastoma multiforme cells.
Knockdown of Tousled‑like kinase 1 inhibits survival of glioblastoma multiforme cells. Int J Mol Med. 2020 May 28;: Authors: Ibrahim K, Abdul Murad NA, Harun R, Jamal R Abstract Glioblastoma multiforme (GBM) is an aggressive type of brain tumour that commonly exhibits resistance to treatment. The tumour is highly heterogenous and complex kinomic alterations have been reported leading to dysregulation of signalling pathways. The present study aimed to investigate the novel kinome pathways and to identify potential therapeutic targets in GBM. Meta‑analysis using Oncomine identified 113 upregulated k...
Source: International Journal of Molecular Medicine - May 27, 2020 Category: Molecular Biology Authors: Ibrahim K, Abdul Murad NA, Harun R, Jamal R Tags: Int J Mol Med Source Type: research

TROY signals through JAK1-STAT3 to promote glioblastoma cell migration and resistance.
Abstract Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and carries a discouraging prognosis. Its aggressive and highly infiltrative nature renders the current standard treatment of maximal surgical resection, radiation, and chemotherapy relatively ineffective. Identifying the signaling pathways that regulate GBM migration/invasion and resistance is required to develop more effective therapeutic regimens to treat GBM. Expression of TROY, an orphan receptor of the TNF receptor superfamily, increases with glial tumor grade, inversely correlates with patient overall survival, stimulates...
Source: Neoplasia - July 2, 2020 Category: Cancer & Oncology Authors: Ding Z, Kloss JM, Tuncali S, Tran NL, Loftus JC Tags: Neoplasia Source Type: research

Cancers, Vol. 12, Pages 3781: Novel Thiosemicarbazones Sensitize Pediatric Solid Tumor Cell-Types to Conventional Chemotherapeutics through Multiple Molecular Mechanisms
We examined the effects of combining the novel thiosemicarbazones, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), or its analog, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), with the standard chemotherapies, celecoxib (CX), etoposide (ETO), or temozolomide (TMZ). These combinations were analyzed for synergism to inhibit proliferation of three pediatric tumor cell-types, namely osteosarcoma (Saos-2), medulloblastoma (Daoy) and neuroblastoma (SH-SY5Y). In terms of mechanistic dissection, this study discovered novel thiosemicarbazone targets not previously identified and which are importa...
Source: Cancers - December 15, 2020 Category: Cancer & Oncology Authors: Silvia Paukovcekova Jan Skoda Jakub Neradil Erika Mikulenkova Petr Chlapek Jaroslav Sterba Des R. Richardson Renata Veselska Tags: Article Source Type: research

Regulation of temozolomide resistance in glioma cells via the RIP2/NF- κB/MGMT pathway.
CONCLUSION: We report that the RIP2/NF-κB/MGMT signaling pathway is involved in the regulation of TMZ resistance. Interference with NF-κB or MGMT activity could constitute a novel strategy for the treatment of RIP2-positive TMZ-resistant glioma. PMID: 33460245 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - January 18, 2021 Category: Neuroscience Authors: Hu YH, Jiao BH, Wang CY, Wu JL Tags: CNS Neurosci Ther Source Type: research

Molecular Characterization of AEBP1 at Transcriptional Level in Glioma
CONCLUSION: In summary, AEBP1 was related with GSC-induced TMZ resistance. Our study showed that AEBP1 might be an oncogene and a new effective therapeutic target for the treatment of glioma.PMID:34373835 | PMC:PMC8349255 | DOI:10.1155/2021/5579359
Source: Cell Research - August 10, 2021 Category: Cytology Authors: Kuanyu Wang Ruoyu Huang Xuezhi Tong Zhiliang Wang Shibin Sun Chenxing Wu Source Type: research

Anti-Proliferative Effects of E2F1 Suppression in Glioblastoma Cells
Glioblastoma (GBM) is an aggressive malignant brain tumor; surgery, radiation, and temozolomide still remain the main treatments. There is evidence that E2F1 is overexpressed in various types of cancer, including GBM. E2F1 is a transcription factor that controls the cell cycle progression and regulates DNA damage responses and the proliferation of pluripotent and neural stem cells. To test the potentiality of E2F1 as molecular target for GBM treatment, we suppressed theE2F1 gene (siRNA) in the U87MG cell line, aiming to inhibit cellular proliferation and modulate the radioresistance of these cells. Following E2F1 suppressi...
Source: Cytogenetic and Genome Research - September 3, 2021 Category: Genetics & Stem Cells Source Type: research

Treatment options for progression or recurrence of glioblastoma: a network meta-analysis
CONCLUSIONS: For treatment of first recurrence of GBM, among people previously treated with surgery and standard chemoradiotherapy, the combination treatments evaluated did not improve overall survival compared with LOM monotherapy and were often associated with a higher risk of severe adverse events. Limited evidence suggested that re-operation with or without re-irradiation and chemotherapy may be suitable for selected candidates. Evidence on second recurrence is sparse. Re-irradiation with or without bevacizumab may be of value in selected individuals, but more evidence is needed.PMID:34559423 | PMC:PMC8121043 | DOI:10....
Source: Cochrane Database of Systematic Reviews - September 24, 2021 Category: General Medicine Authors: Catherine McBain Theresa A Lawrie Ewelina Rogozi ńska Ashleigh Kernohan Tomos Robinson Sarah Jefferies Source Type: research

Cancers, Vol. 14, Pages 1984: SRPX Emerges as a Potential Tumor Marker in the Extracellular Vesicles of Glioblastoma
Okay Saydam Extracellular vesicles (EVs) may be used as a non-invasive screening platform to discover markers associated with early diagnosis, prognosis, and treatment response. Such an approach is invaluable for diseases such as glioblastoma, for which only a few non-invasive diagnostic or prognostic markers are available. We used mass spectrometry to analyze proteomics profiles of EVs derived from four glioblastoma cell lines and human primary astrocytes (HPAs) and found that SRPX is the only protein enriched in the majority of glioblastoma EVs that was absent in the HPA-derived EVs. Then, we evaluated the relationsh...
Source: Cancers - April 14, 2022 Category: Cancer & Oncology Authors: Elisabet Ampudia-Mesias Samia El-Hadad Charles Scott Cameron Adelheid W öhrer Thomas Str öbel Nurten Saydam Okay Saydam Tags: Article Source Type: research